Shattuck Labs announces Phase 2 trial and executive appointment
Shattuck Labs said it will start a Phase 2 clinical trial of SL-325 in hidradenitis suppurativa and appointed Shoba Ravichandran, M.D., as senior vice president of clinical development.
Story updates
11:09:07 AM UTC
SquawkNews
Shattuck Labs will initiate a randomized Phase 2 trial of SL-325 in hidradenitis suppurativa in 2026, with 16-week data expected in H1 2028, and reaffirmed cash runway into 2029. Shoba Ravichandran, M.D., was appointed SVP, Clinical Development.Material DetailsContext by AI AnalystThis is an early…